Dublin, March 11, 2020 (GLOBE NEWSWIRE) -- The "Global Psychiatry Partnering 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Global Psychiatry Partnering 2014 to 2020 provides the full collection of Psychiatry disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

  • Trends in Psychiatry dealmaking in the biopharma industry since 2014
  • Analysis of Psychiatry deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Psychiatry deal contract documents
  • Comprehensive access to over 600 Psychiatry deal records
  • The leading Psychiatry deals by value since 2014
  • Most active Psychiatry dealmakers since 2014

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Psychiatry disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Psychiatry deals.

The report presents financial deal terms values for Psychiatry deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Psychiatry dealmaking trends.

  • Chapter 1 provides an introduction to the report.
  • Chapter 2 provides an overview of the trends in Psychiatry dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
  • Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
  • Chapter 4 provides a review of the leading Psychiatry deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Psychiatry dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Chapter 5 provides comprehensive access to Psychiatry deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
  • Chapter 6 provides a comprehensive directory of all Psychiatry partnering deals by specific Psychiatry target announced since 2014. The chapter is organized by specific Psychiatry therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Psychiatry partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Psychiatry partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Psychiatry technologies and products.

Report Scope

The report includes deals for the following indications: Akathisia, Anxiety disorder, Generalised anxiety disorder, Panic disorder, Post traumatic stress disorder, Attention deficit hyperactivity disorder, Bipolar disorder, Chronic fatigue syndrome, Cognitive impairment, Delirium, Dementia, Alzheimers, Dementia with lewy bodies, Vascular dementia, Depression, Dystonia, Eating disorder, Anorexia, Bulimia, Learning disability, Aspergers, Autism, Mania, Obsessive compulsive disorder, Personality disorder, Schizophrenia, Sleep disorders, Insomnia, Narcolepsy, Sleep apnoea, Tardive dyskinesia, Tourettes, plus other psychiatric indications.

Available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Global Psychiatry Partnering 2014-2020 provides comprehensive access to available deals and contract documents for over 600 psychiatry deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

  • 3B Medical
  • 3PrimeDx
  • 23andMe
  • Abbvie
  • AbCellera
  • Academic Drug Discovery Consortium
  • Accera Pharmaceuticals
  • Acer Therapeutics
  • AC Immune
  • Actavis (name changed to Allergan)
  • Actelion
  • AcuraStem
  • AdAlta
  • Adamas Pharmaceuticals
  • Adare Pharmaceuticals
  • Addex Therapeutics
  • Adimab
  • Admera Health
  • Advanced Cooling Therapy
  • Advocate Health Care
  • ADx Healthcare
  • Aelan Cell Technologies
  • Aequus Pharmaceuticals
  • Aerial BioPharma
  • Affymetrix
  • Agena Bioscience
  • AgeneBio
  • Agilis Biotherapeutics
  • Aiforia Technologies
  • Air Force General Hospital
  • AIT Laboratories
  • Akili Interactive Labs
  • Alector
  • Alexion Pharmaceuticals
  • Alexza Pharmaceuticals
  • Alkahest
  • Alkermes
  • Allen Institute for Brain Science
  • Allergan
  • Alphaeon
  • ALS Association
  • Alzamend Neuro
  • Alzeca Biosciences
  • Alzecure Foundation
  • Alzheimer's Association
  • Alzheimer's Drug Discovery Foundation
  • Alzheimer's Foundation of America
  • Alzheimer's Research UK
  • Alzheimer Society Research
  • Alzheimers Research UK
  • AlzProtect
  • Alzyn
  • Amarantus BioSciences
  • Ambry Genetics
  • American Diabetes Association
  • American Heart/Stroke Association
  • American Sleep Apnea Association
  • American Well
  • Amgen
  • Amherst Pharmaceuticals
  • Amneal Pharmaceuticals
  • Amorsa Therapeutics
  • Amydis Diagnostics
  • Analytical Testing Laboratory
  • Anavex Life Sciences
  • Andor Pharmaceuticals
  • ANI Pharmaceuticals
  • Apnea Sciences
  • Apotex
  • APRINOIA Therapeutics
  • Aptinyx
  • Aquinnah Pharmaceuticals
  • Araclon Biotech
  • ARCH Personalized Medicine Initiative
  • Arena Pharmaceuticals
  • Arizona State University
  • Armor
  • Artelo Biosciences
  • Association for Frontotemporal Degeneration
  • Assurex Health
  • Assuta Medical Centers
  • Astellas Pharma
  • Astex Pharmaceuticals
  • AstraZeneca
  • Aurora Cannabis
  • Australian Imaging
  • Biomarker & Lifestyle Flagship Study of Ageing (AIBL)
  • Autifony Therapeutics
  • Autism Speaks
  • AXIM Biotechnologies
  • AxoSim
  • Axxam
  • Bachmann-Strauss Dystonia & Parkinson Foundation
  • Bain Capital
  • Banner Alzheimer's Institute
  • Banner Health
  • Baylor College
  • BDD Pharma
  • Beijing Double-Crane Pharmaceutical
  • Beijing Leadman Biochemistry
  • Berg
  • Best Choice
  • Bestmed
  • Beurer
  • Biametrics
  • Bicycle Therapeutics
  • Bill and Melinda Gates Foundation
  • BioArctic Neuroscience
  • biOasis Technologies
  • Biocodex
  • Biodextris
  • Biogen
  • Biohaven Pharmaceutical Holding
  • Biomedical Catalyst Fund (UK)
  • BioMed X Innovation Center
  • Bionomics
  • Biopharmaceuticals Australia
  • Bioprojet
  • BioTie Therapies
  • Blackfynn
  • BlackThorn Therapeutics
  • Blake Insomnia Therapeutics
  • Blum Center for Health
  • BMC Medical
  • Boehringer Ingelheim
  • Boston Scientific
  • Boston University
  • Boston University School of Medicine
  • Bracket
  • Brain & Behavior Research Foundation
  • Brain Balance Achievement Centers
  • Brain Biomarker Solutions in Gothenburg
  • Brainsway
  • Breakthrough Diagnostics
  • Breathe ECig
  • Breckenbridge Pharmaceutical
  • Brigham and Women's Hospital
  • BrightFocus Foundation
  • Bristol-Myers Squibb
  • Broad Institute
  • Buck Institute for Age Research
  • BullFrog AI
  • C2N Diagnostics
  • C4 Therapeutics
  • C4X Discovery
  • Cadent
  • Calico
  • Camargo Pharmaceutical Services
  • Cambridge Brain Sciences
  • Cambridge Cognition
  • CannRx Technology
  • Cannvalate
  • Caprion Biosciences
  • Caputron Medical
  • Cardiff University
  • CareCentrix
  • CareFusion
  • Carna BioSciences
  • Case Western Reserve University
  • Casma Therapeutics
  • Catalent Pharma Solutions
  • CavoGene LifeSciences
  • CEITEC
  • Celgene
  • Cellectricon
  • Cellular Dynamics International
  • Centene
  • Center for iPS Cells Research and Application
  • Cerebain
  • Cerebral Therapeutics
  • Cerecor
  • Cerevel Therapeutics
  • Certainty Health
  • Cerveau Technologies
  • Cervel Neurotech
  • Chaperone Technologies
  • ChemDiv
  • Children's Hospital Boston
  • Children's Minnesota
  • Chronos Therapeutics
  • Chugai Pharma Marketing
  • Cingulate Therapeutics (CTx)
  • Circuit Therapeutics
  • City of Hope
  • Cleveland Clinic
  • Click Therapeutics
  • Clinical Imaging Research Centre
  • Cloud Pharmaceuticals
  • CluePoints
  • Cogito
  • Cognetivity Neurosciences
  • Cognition Kit
  • Cognition Therapeutics
  • Cognoa
  • CogState
  • Cohen Veterans Bioscience
  • Columbia University
  • Complement Pharma
  • Compumedics
  • Confo Therapeutics
  • Connecticut Children's Medical Center
  • Context Therapeutics
  • Coriell Institute for Medical Research
  • Corium International
  • Cortex Pharmaceuticals
  • Cortexyme
  • Cortice Biosciences
  • Corvida Medical
  • COTA
  • Courtagen Life Sciences
  • CRC Health
  • CRISPR Therapeutics
  • Crossbeta Biosciences
  • CryoPort
  • Cure Alzheimer's Fund
  • CURE Pharmaceutical
  • Cypralis
  • Cyrenaic Pharmaceuticals
  • Cytox
  • and many, many more...

For more information about this report visit www.researchandmarkets.com/r/xccyjm

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900



Source link